<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Low-dose warfarin plus aspirin is not optimal in high-risk AF</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Low-dose warfarin plus aspirin is not optimal in high-risk AF</h1>
<div class="graphic"><div class="figure"><div class="ttl">Low-dose warfarin plus aspirin is not optimal in high-risk AF</div><div class="cntnt"><img src="data:png;base64,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"/></div><div class="graphic_lgnd">Cumulative event rate of patients with AF at high risk for thromboembolism in the SPAF III trial. High risk was defined as the presence of at least 1 of the following: previous thromboembolism, female older than 75 years of age, heart failure or severe left ventricular systolic dysfunction, and systolic pressure &gt;160 mmHg. There was a much lower incidence of events with standard adjusted-dose warfarin therapy (INR 2 to 3) compared with treatment with aspirin and low-dose warfarin (INR 1.2 to 1.5; p&lt;0.0001).</div><div class="graphic_footnotes">AF: atrial fibrillation; INR: international normalized ratio.</div><div class="graphic_reference">Data from Stroke Prevention in Atrial Fibrillation Investigators. Lancet 1996; 348:633.</div><div id="graphicVersion">Graphic 72790 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
